Opinion|Videos|December 16, 2024
Comprehensive Supportive Care for Metastatic HER2+ Breast Cancer
Panelists discuss the supportive care considerations for patients being treated for metastatic HER2+ breast cancer, including the roles of nutrition, exercise, and other integrative approaches in enhancing patient well-being and treatment outcomes.
Advertisement
Episodes in this series
Dr Iyengar asks Odessa Williams: What other supportive care do you consider for patients being treated for metastatic HER2+ breast cancer? (eg, nutrition, exercise, etc.etc)?
Advertisement
Related to this article
Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.
In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.
Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
Advertisement
Advertisement
Trending on CancerNetwork
1
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
2
FDA OKs Pirtobrutinib in Frontline CLL/SLL
3
FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC
4
Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?
5